Therapeutic use of chemokines

被引：9

作者：

Hogaboam, CM ^{[1
]}

Bone-Larson, C ^{[1
]}

Matsukawa, A ^{[1
]}

Steinhauser, ML ^{[1
]}

Blease, K ^{[1
]}

Lukacs, NW ^{[1
]}

Kunkel, SL ^{[1
]}

机构：

[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA

来源：

CURRENT PHARMACEUTICAL DESIGN | 2000年 / 6卷 / 06期

关键词：

D O I：

10.2174/1381612003400605

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Chemokines are involved in a number of pathological processes, and therefore represent important targets. However, it has also become apparent that chemokines have exciting therapeutic applications in inflammatory, infectious and cancer-related diseases. The following review will highlight the application of novel therapies including viral-encoded, recombinant, and genetically engineered chemokines to a number of diseases or disorders. Advances in the application of novel chemokine delivery procedures both at the research bench and the clinical bedside will also be discussed. Overall, the utilization of chemokines to prevent and treat disease has tremendous potential.

引用

页码：651 / 663

页数：13

共 113 条

[1]

Andrew DP, 1998, J IMMUNOL, V161, P5027

[2]

[Anonymous], 1999, ANNU REV MED

[3] Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer [J].

Arenberg, DA ;

Keane, MP ;

DiGiovine, B ;

Kunkel, SL ;

Morris, SB ;

Xue, YY ;

Burdick, MD ;

Glass, MC ;

Iannettoni, MD ;

Strieter, RM .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (03) :465-472

[4] Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases [J].

Arenberg, DA ;

Kunkel, SL ;

Polverini, PJ ;

Morris, SB ;

Burdick, MD ;

Glass, MC ;

Taub, DT ;

Iannettoni, MD ;

Whyte, TI ;

Strieter, RM .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :981-992

[5] Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC [J].

Baba, M ;

Imai, T ;

Nishimura, M ;

Kakizaki, M ;

Takagi, S ;

Hieshima, K ;

Nomiyama, H ;

Yoshie, O .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (23) :14893-14898

[6] ACTIVATION OF DUAL T-CELL SIGNALING PATHWAYS BY THE CHEMOKINE RANTES [J].

BACON, KB ;

PREMACK, BA ;

GARDNER, P ;

SCHALL, TJ .

SCIENCE, 1995, 269 (5231) :1727-1730

[7] Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas [J].

Bao, JJ ;

Zhang, WW ;

Kuo, MT .

HUMAN GENE THERAPY, 1996, 7 (03) :355-365

[8] A randomized phase II study of BB-10010:: a variant of human macrophage inflammatory protein-1α for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer [J].

Bernstein, SH ;

Eaves, CJ ;

Herzig, R ;

Fay, J ;

Lynch, J ;

Phillips, GL ;

Christiansen, N ;

Reece, D ;

Ericson, S ;

Stephan, M ;

Kovalsky, M ;

Hawkins, K ;

Rasmussen, H ;

Devos, A ;

Herzig, GP .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :888-895

[9]

BIANCHI G, 1996, EUR J IMMUNOL, V26, P3238

[10] Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity [J].

Biragyn, A ;

Tani, K ;

Grimm, MC ;

Weeks, S ;

Kwak, LW .

NATURE BIOTECHNOLOGY, 1999, 17 (03) :253-258

← 1 2 3 4 5 6 7 8 9 10 →